Ovation.io and Illumina Collaborate to Advance Genomic Data Research
Ovation.io and Illumina (NASDAQ: ILMN) announced a collaboration to advance precision medicine by combining Illumina's next-generation sequencing platforms with Ovation's 1.6+ million sample biobank. The partnership aims to create comprehensive clinico-genomic datasets for non-oncology indications where current data is insufficient.
The collaboration will initially focus on pilot datasets in liver disease, chronic kidney disease, and GLP-1 receptor agonist treated patients. Building on Ovation's existing IBD Omics product, the partnership will help identify optimal drug targets and biomarkers, potentially reducing development costs and improving treatment success rates. The initiative will leverage de-identified, consented samples linked to longitudinal clinical data, including medical records, laboratory results, and claims.
Ovation.io e Illumina (NASDAQ: ILMN) hanno annunciato una collaborazione per far progredire la medicina di precisione combinando le piattaforme di sequenziamento di nuova generazione di Illumina con la biobanca di oltre 1,6 milioni di campioni di Ovation. L'obiettivo della partnership è creare dataset clinico-genomici completi per indicazioni non oncologiche dove i dati attuali sono insufficienti.
La collaborazione si concentrerà inizialmente su dataset pilota relativi a malattie del fegato, malattie renali croniche e pazienti trattati con agonisti del recettore GLP-1. Basandosi sul prodotto IBD Omics esistente di Ovation, la partnership aiuterà a identificare i target farmacologici e i biomarcatori ottimali, potenzialmente riducendo i costi di sviluppo e migliorando i tassi di successo del trattamento. L'iniziativa utilizzerà campioni de-identificati e consapevoli, collegati a dati clinici longitudinali, inclusi cartelle cliniche, risultati di laboratorio e richieste di risarcimento.
Ovation.io e Illumina (NASDAQ: ILMN) anunciaron una colaboración para avanzar en la medicina de precisión combinando las plataformas de secuenciación de próxima generación de Illumina con el biobanco de más de 1.6 millones de muestras de Ovation. El objetivo de la asociación es crear conjuntos de datos clinico-genómicos completos para indicaciones no oncológicas donde los datos actuales son insuficientes.
La colaboración se centrará inicialmente en conjuntos de datos piloto en enfermedades del hígado, enfermedad renal crónica y pacientes tratados con agonistas del receptor GLP-1. Basándose en el producto IBD Omics existente de Ovation, la asociación ayudará a identificar los objetivos farmacológicos y los biomarcadores óptimos, lo que podría reducir los costos de desarrollo y mejorar las tasas de éxito del tratamiento. La iniciativa aprovechará las muestras desidentificadas y consentidas, vinculadas a datos clínicos longitudinales, incluyendo registros médicos, resultados de laboratorio y reclamaciones.
Ovation.io와 Illumina (NASDAQ: ILMN)은 Illumina의 차세대 시퀀싱 플랫폼과 Ovation의 160만 샘플 이상의 생물은행을 결합하여 정밀 의학을 발전시키기 위한 협업을 발표했습니다. 이 파트너십은 현재 데이터가 부족한 비종양적 적응증에 대한 포괄적인 클리니코-유전체 데이터 세트를 만드는 것을 목표로 합니다.
협업은 처음에 간 질환, 만성 신장 질환 및 GLP-1 수용체 작용제 치료 환자에 대한 파일럿 데이터 세트에 초점을 맞출 것입니다. Ovation의 기존 IBD Omics 제품을 기반으로 하여, 이 파트너십은 최적의 약물 타겟 및 바이오마커를 식별하는 데 도움을 줄 것이며, 개발 비용을 줄이고 치료 성공률을 높일 수 있을 것입니다. 이 이니셔티브는 의료 기록, 실험실 결과 및 청구를 포함한 종단적 임상 데이터와 연계된 비식별화된 동의된 샘플을 활용할 것입니다.
Ovation.io et Illumina (NASDAQ: ILMN) ont annoncé une collaboration pour faire avancer la médecine de précision en combinant les plateformes de séquençage de nouvelle génération d'Illumina avec la biobanque de plus de 1,6 million d'échantillons d'Ovation. Le partenariat vise à créer des ensembles de données clinico-génomiques complets pour des indications non-oncologiques où les données actuelles sont insuffisantes.
La collaboration se concentrera d'abord sur des ensembles de données pilotes concernant les maladies du foie, la maladie rénale chronique et les patients traités par des agonistes des récepteurs GLP-1. S'appuyant sur le produit IBD Omics existant d'Ovation, ce partenariat aidera à identifier les cibles médicamenteuses et les biomarqueurs optimaux, ce qui pourrait réduire les coûts de développement et améliorer les taux de réussite des traitements. L'initiative exploitera des échantillons anonymisés et consentis, liés à des données cliniques longitudinales, y compris des dossiers médicaux, des résultats de laboratoire et des demandes de remboursement.
Ovation.io und Illumina (NASDAQ: ILMN) haben eine Zusammenarbeit angekündigt, um die präzise Medizin voranzutreiben, indem sie die Next-Generation-Sequenzierungsplattformen von Illumina mit Ovations Biobank von über 1,6 Millionen Proben kombinieren. Ziel der Partnerschaft ist es, umfassende klinisch-genomische Datensätze für nicht-onkologische Indikationen zu erstellen, bei denen die aktuellen Daten unzureichend sind.
Die Zusammenarbeit wird sich zunächst auf Pilotdatensätze zu Lebererkrankungen, chronischer Nierenerkrankung und Patienten, die mit GLP-1-Rezeptoragonisten behandelt werden, konzentrieren. Auf der bestehenden IBD Omics-Plattform von Ovation aufbauend, wird die Partnerschaft helfen, optimale Arzneimittelziele und Biomarker zu identifizieren, was potenziell die Entwicklungskosten senken und die Erfolgsquote bei Behandlungen verbessern kann. Die Initiative wird anonymisierte, einwilligte Proben nutzen, die mit longitudinalen klinischen Daten verknüpft sind, einschließlich medizinischer Aufzeichnungen, Laborergebnissen und Abrechnungen.
- Access to large-scale biobank with 1.6+ million consented samples
- Expansion into new therapeutic areas beyond oncology
- Potential to reduce drug development costs through better target identification
- Integration of comprehensive clinical data with genomic information
- None.
Insights
This collaboration marks a significant strategic expansion for Illumina into non-oncology therapeutic areas. The partnership with Ovation.io provides access to a substantial biobank of 1.6+ million samples, enabling the creation of comprehensive clinico-genomic datasets across various diseases. The initial focus on liver disease, chronic kidney disease and GLP-1 treated patients represents high-growth therapeutic areas with significant market potential.
The deal enhances Illumina's competitive position in the precision medicine market by expanding beyond its traditional strongholds in oncology and rare diseases. Access to Ovation's longitudinal clinical data coupled with genomic sequencing could accelerate drug target discovery and biomarker development, potentially leading to increased NGS instrument and consumables sales for Illumina. This partnership model could be replicated with other biobanks to further expand market reach.
The collaboration positions Illumina to tap into the rapidly growing precision medicine market in metabolic and cardiovascular diseases. The initial focus on GLP-1 treated patients is particularly strategic given the explosive growth in this therapeutic class, with the global GLP-1 market projected to reach
The scalable nature of this partnership, with potential to expand beyond the initial 1.6M samples, provides a clear path for long-term revenue growth. This move diversifies Illumina's revenue streams beyond traditional genomic sequencing services into high-value data and insights for drug development.
The focus of the collaboration will be on non-oncology indications where there are insufficient clinico-genomic datasets to advance genomically-based research goals. The collaboration will leverage Illumina’s next-generation sequencing (NGS) platforms alongside Ovation’s biobank, that contains 1.6+ million de-identified, consented and tokenized samples, with the goal of providing life sciences researchers with high-quality genomic data linked to rich, longitudinal clinical data at scale (e.g., electronic medical records, laboratory results and claims). The resulting human genomics data will help drive the identification of optimal targets across indications, significantly improving the success of existing treatments and the development of new therapeutics.
This builds on Ovation’s existing IBD Omics product featuring whole genome sequencing and RNA-seq from IBD patients. Ovation’s IBD Omics product has been created to identify novel biomarkers for disease progression and therapy response in both Crohn’s Disease and Ulcerative Colitis.
The first phase of the collaboration will focus on creating pilot datasets in liver disease, chronic kidney disease and glucagon-like peptide-1 (GLP-1) receptor agonist treated patients to demonstrate the quality, depth and diversity of data derived from the Ovation biobank. Illumina and Ovation will then seek industry partners to sequence the most underrepresented and high value patient populations.
“Applying human genomic data in oncology and rare disease research has resulted in new personalized medicines that have proven transformative for patient outcomes. Our collaboration with Ovation will add to the depth and diversity of data available to drive research in metabolic diseases, cardiology, immunology and other indications,” said Todd Christian, senior vice president, Services, Arrays, and Genomic Access businesses at Illumina. “These types of collaborations build on our mission to unlock the power of the genome by expanding genomic healthcare insights across a wider range of conditions, accelerating the impact of precision medicines.”
“Our collaboration with Illumina represents a significant milestone in our goal to revolutionize genomic data and its availability for researchers,” said Curt Medeiros, CEO of Ovation. “By integrating Illumina’s industry-leading sequencing capabilities with our technology-enabled platform to source high volumes of consented patient samples, we have the opportunity to scale this partnership well beyond the initial 1.6M samples in the Ovation biobank, and propel the amount of human genomic data available to researchers."
About Ovation
Ovation is a genomic data company committed to unlocking the potential of human genomic data at scale and accelerating precision medicine development.
By providing access to high-quality genomic data linked to rich, longitudinal phenotypic data at scale, Ovation allows life sciences researchers to advance drug discovery and development more efficiently. Ovation’s cloud-based LIMS and Ovation Research Network, enable a diverse network of clinical laboratories to quickly adopt innovative molecular tests while biobanking and transforming samples to be used for research.
For more information about Ovation, visit www.ovation.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20241216497421/en/
Ovation Media:
David Moyer
David.moyer@ovation.io
Source: Ovation.io, Inc.
FAQ
What is the purpose of the Illumina (ILMN) and Ovation.io collaboration?
How many samples are available in Ovation's biobank for the ILMN collaboration?
Which disease areas will the ILMN-Ovation collaboration initially focus on?
What types of clinical data will be linked to genomic information in the ILMN collaboration?
How will the ILMN-Ovation partnership impact drug development?
